. 2021 May 12;76(4):277–283. doi: 10.1016/j.therap.2021.05.004

Table 3.

Effectiveness of SARS-CoV-2 vaccination in real life.

Settings	Vaccinated population	Vaccine	Symptomatic and asymptomatic infections (95% CI)	Severe infections (95% CI)	Mortality (95% CI)
Clalit Health Services Israel [17]	596,618	BNT 162 b2	92% (88–95)^a	92% (75–100)^a	84% (44–100)^b
Mayo Clinic Health System USA [18]	31,069	BNT 162 b2 or mRNA 1273	89% (68–97)^a	60% (14–79)^a	None
Mass vaccination Scotland [19]	1,331,993	BNT 162 b2 or ChAdOx1nCov-19	ND	91% (95% CI 85–94)^c 88% (95% CI 75–94)^c	ND
Health Care Workers England [20]	20,641	BNT 162 b2 or ChAdOx1nCov-19	85% (74–96)^a	None	None

CI: confidence interval; ND: not determined; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Seven to 14 days after the last dose.

21 to 27 days after the first dose.

Reduction in hospitalization 28–34 days after the first dose.